Riskpilot← Back to searchSign inGet full accessGenomain AB
ABActiveOrg 5594884446Pumpgatan 1Business and other management consultancy activities · NACE 7020Est. 20241-4 employees
Revenue 2025
SEK 634K
EBITDA margin
-186.6%
Equity ratio
1.4%
Financial strength
Net profit 2025
SEK -1,3M
| Revenue | SEK 634K | — |
| EBITDA | SEK -1,2M | — |
| Net profit | SEK -1,3M | — |
| Total assets | SEK 1,9M | — |
| Equity | SEK 27K | — |
| Employees | — | — |
Legal name
Genomain AB
Org number
5594884446
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
1 juli 2024
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling och försäljning av affärssystem, konsultation samt rådgivning och därmed förenlig verksamhet.
Address
Pumpgatan 1
Email
info@genomain.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | 634 |
| Staff expenses | −1 393 |
| EBITDA | −1 183 |
| Depreciation & amort. | −54 |
| EBIT | −1 238 |
| Net financials | −35 |
| Profit before tax | −1 273 |
| Tax | — |
| Net profit | −1 273 |
| Item | 2025 |
|---|---|
| Total assets | 1 933 |
| Equity | 27 |
| Long-term debt | 1 125 |
| Short-term debt | 781 |
| Total debt | 1 906 |
EBITDA margin
-186.6%
This company
15.8%
Market median
-1281% vs market
20252025
Equity ratio
1.4%
This company
38.2%
Market median
-96% vs market
20252025
Return on equity
-4767.5%
This company
18.4%
Market median
-26010% vs market
20252025
Net profit margin
-200.8%
This company
8.1%
Market median
-2579% vs market
20252025
Asset turnover
0.33×
This company
1.12×
Market median
-71% vs market
20252025
Debt / equity
71.36×
This company
0.62×
Market median
-11410% vs market
20252025
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SA Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Board of Directors | 2024 | |
| Former (2) | ||
| Deputy Board Member | 2024 – 2024 | |
| Board of Directors | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Genomain AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Saman Andishmand | Chief Executive Officer | 0 companies |
| Eva Margareta Eljans | Deputy Board Member | 0 companies |
| Lars Kristian Stensjö | Chairman | 0 companies |
| Lars Magnus Jildin | Board of Directors | 0 companies |
| Anita Helena Berggren | Board of Directors | 0 companies |
| Anders Johan Björnarås Roupe | Board of Directors | 0 companies |